Perspective Therapeutics ... (CATX)

AI Score

Unlock

2.21

-0.09 (-3.91%)

At close: Mar 28, 2025, 3:59 PM

2.23

0.60%

After-hours: Mar 28, 2025, 06:24 PM EDT

-3.91% (1D)

Bid	2.2
Market Cap	149.71M
Revenue (ttm)	322.49K
Net Income (ttm)	-61.04M
EPS (ttm)	-1.22
PE Ratio (ttm)	-1.82
Forward PE	-2.86
Analyst	Buy

Ask	2.56
Volume	601,367
Avg. Volume (20D)	780,076
Open	2.33
Previous Close	2.30
Day's Range	2.19 - 2.35
52-Week Range	2.19 - 19.10
Beta	1.26

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facil...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Nov 10, 2005

Employees 116

Stock Exchange AMEX

Ticker Symbol CATX

Website https://www.perspectivetherapeutics.com

Full Company Profile

Analyst Forecast

According to 11 analyst ratings, the average rating for CATX stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 599.77% from the latest price.

Stock Forecasts

Earnings Surprise

Perspective Therapeutics has released their quartely earnings on Mar 26, 2025:

Revenue of $234K misses estimates by $68.51K, with -88.50% YoY decline.

EPS of -0.6 misses estimates by -0.34, with 33.33% YoY growth.

Next Earnings Release

Perspective Therapeutics Inc. is scheduled to release its earnings on May 14, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

-51.38%

Perspective Therapeutics shares are trading lower.... Unlock content with Pro Subscription

7 months ago

+0.58%

Perspective Therapeutics shares are trading lower. The company reported Q2 financial results.

News

3 months ago · seekingalpha.com

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Perspective Therapeutics' radiopharmaceuticals offer potential oncology applications by combining diagnostics with targeted therapeutics. I like the company's theranostics approach that delivers radia...